OncoMatch/Clinical Trials/NCT05884320
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
Is NCT05884320 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Sacituzumab Govitecan for gland.
Treatment: Sacituzumab Govitecan — To learn if sacituzumab govitecan can help to control salivary gland cancer.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Allowed: HER2 (ERBB2) amplification
Allowed: HER2 (ERBB2) overexpression (3+ by ihc)
Disease stage
Metastatic disease required
Grade: intermediatehigh
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: HER2-targeted therapy — R/M HER2+ tumors only
HER2 overexpressing (3+ by IHC) or amplified tumors, must have received at least one prior line with a HER2-targeting agent OR must have a contra-indication for HER-2 targeted therapy
Cannot have received: radiation therapy
Prior radiation therapy (or other non-systemic therapy) within 2 weeks prior to enrollment
Cannot have received: chemotherapy
Exception: Cohort 2: up to 3 lines of palliative chemotherapy in the R/M setting allowed
Prior anticancer therapy including, but not limited to, chemotherapy, immunotherapy, or investigational agents within 4 weeks or 5 half-lives prior to SG treatment
Cannot have received: immunotherapy
Prior anticancer therapy including, but not limited to, chemotherapy, immunotherapy, or investigational agents within 4 weeks or 5 half-lives prior to SG treatment
Cannot have received: investigational agent
Prior anticancer therapy including, but not limited to, chemotherapy, immunotherapy, or investigational agents within 4 weeks or 5 half-lives prior to SG treatment
Lab requirements
Blood counts
hemoglobin ≥ 9 g/dl; absolute neutrophil count ≥ 1 x 10^9/ml without growth factor support for 28 days; platelets ≥ 100 x 10^9/ml without platelet transfusion for 28 days
Kidney function
creatinine clearance ≥ 30 ml/min as assessed by the cockcroft-gault equation
Liver function
ast and alt ≤ 2.5 x uln or ≤ 5 x uln in patients with liver metastases; total bilirubin ≤ 1.5 x uln or ≤ 3.0 x uln and primarily unconjugated if patient has a documented history of gilbert's syndrome or genetic equivalent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify